Abstract
Purpose
The field of oncofertility has maintained an important focus on improving access, yet standardized practices are lacking. To assess how female cancer patients are provided oncofertility care, we sought to determine provider-level differences and whether there are physician or practice characteristics that predict these variations.
Methods
A cross-sectional survey was sent to SREI members. The survey included fifteen questions about physician practice characteristics and oncofertility cryopreservation protocols. Topics included ovarian stimulation protocols, fertilization techniques, stage of embryo cryopreservation, routine use of pre-implantation genetic testing for aneuploidy (PGT-A), and ovarian tissue cryopreservation (OTC). Statistical analyses assessed whether practice setting, geographic region, time in practice, and mandatory state insurance coverage had effects on cryopreservation protocols.
Results
A total of 141 (17%) from diverse REI practice backgrounds completed the survey. The median number of new female oncofertility consults per year was 30 (range 1 to 300). Providers in academic settings treated more patients (median 40 vs. 15, p < 0.001). Providers in academic settings more often use gonadotropin-releasing hormone agonists (85% vs. 52%, p < 0.001) and perform OTC (41% vs. 4%, p < 0.001). Providers in academic practices were less likely to perform intracytoplasmic sperm injection in every cycle (37% vs. 55%, p = 0.032) and less likely to usually advise PGT-A (21% vs. 36%, p = 0.001). Mandated state insurance coverage had no effect on oncofertility practices.
Conclusion
Oncofertility practices vary among providers. Factors such as practice setting and region may affect the services provided. We do not yet know the best practices in oncofertility patients, and future research is needed.
Similar content being viewed by others
References
Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. https://doi.org/10.1200/JCO.2018.78.1914.
Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022–1033. https://doi.org/10.1016/j.fertnstert.2019.09.013
Al-Azawi T, Tavukcuoglu S, Khaki AA, Al HS. Cryopreservation of human oocytes, zygotes, embryos and blastocysts: a comparison study between slow freezing and ultra rapid (vitrification) methods. Middle East Fertil Soc J. 2013;18(4):223–32. https://doi.org/10.1016/j.mefs.2012.10.008.
Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion. Fertil Steril. 2012;98(6):1395–1399. https://doi.org/10.1016/j.fertnstert.2012.08.026
Elnahas A, Alcolak E, Marar EA, et al. Vitrification of human oocytes and different development stages of embryos: An overview. Middle East Fertil Soc J. 2010;15(1):2–9. https://doi.org/10.1016/j.mefs.2010.03.013.
Al-Hasani S, Ozmen B, Koutlaki N, Schoepper B, Diedrich K, Schultze-Mosgau A. Three years of routine vitrification of human zygotes: is it still fair to advocate slow-rate freezing? Reprod Biomed Online. 2007;14(3):288–93. https://doi.org/10.1016/S1472-6483(10)60869-3.
Veeck LL. Does the developmental stage at freeze impact on clinical results post-thaw? Reprod Biomed Online. 2003;6(3):367–74. https://doi.org/10.1016/S1472-6483(10)61859-7.
Marek D, Langley M, Gardner DK, Confer N, Doody KM, Doody KJ. Introduction of blastocyst culture and transfer for all patients in an in vitro fertilization program. Fertil Steril. 1999;72(6):1035–40. https://doi.org/10.1016/S0015-0282(99)00409-4.
Humphreys M, Johnstone E, Letourneau JM. Current approaches to fertility preservation. Clin Obstet Gynecol. 2020;63(4):735–51. https://doi.org/10.1097/GRF.0000000000000574.
Coyne K, Purdy M, Oâ€TMLeary K, Yaklic JL, Lindheim SR, Appiah LA. Challenges and considerations in optimizing ovarian stimulation protocols in oncofertility patients. Front Public Health. 2014;2. https://doi.org/10.3389/fpubh.2014.00246
Donnez J, Dolmans MM. Fertility preservation in women. Campion EW, ed. N Engl J Med. 2017;377(17):1657–1665. https://doi.org/10.1056/NEJMra1614676
Keros V, Xella S, Hultenby K, et al. Vitrification versus controlled-rate freezing in cryopreservation of human ovarian tissue. Hum Reprod. 2009;24(7):1670–83. https://doi.org/10.1093/humrep/dep079.
Dolmans MM, Donnez J. Fertility preservation in women for medical and social reasons: oocytes vs ovarian tissue. Best Pract Res Clin Obstet Gynaecol. 2021;70:63–80. https://doi.org/10.1016/j.bpobgyn.2020.06.011.
Dolmans MM, von Wolff M, Poirot C, et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertil Steril. 2021;115(5):1102–15. https://doi.org/10.1016/j.fertnstert.2021.03.008.
Eliner Y, Palmor M, Amaral B, Penzias AS, Sakkas D, Vaughan DA. Does pgt-a shorten time to live birth? The use of propensity score matching to compare pgt-a versus non-pgt-a patients. Fertil Steril. 2021;116(3, Supplement):e180. https://doi.org/10.1016/j.fertnstert.2021.07.493
Ulrich ND, Raja NS, Moravek MB. A review of fertility preservation in patients with breast cancer. Best Pract Res Clin Obstet Gynaecol. Published online January 2022:S1521693422000116. https://doi.org/10.1016/j.bpobgyn.2022.01.004
Kawwass JF, Shandley LM, Boulet SL, Hipp HS. Oncologic oocyte cryopreservation: national comparison of fertility preservation between women with and without cancer. J Assist Reprod Genet. 2020;37(4):883–90. https://doi.org/10.1007/s10815-020-01715-8.
Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. Published online January 24, 2017:humrep;dew355v1. https://doi.org/10.1093/humrep/dew355
Cobo A, García-Velasco J, Domingo J, Pellicer A, Remohí J. Elective and onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018;33(12):2222–31. https://doi.org/10.1093/humrep/dey321.
Turan V, Quinn MM, Dayioglu N, Rosen MP, Oktay K. The impact of malignancy on response to ovarian stimulation for fertility preservation: a meta-analysis. Fertil Steril. 2018;110(7):1347–55. https://doi.org/10.1016/j.fertnstert.2018.08.013.
Chang EM, Song HS, Lee DR, Lee WS, Yoon TK. In vitro maturation of human oocytes: its role in infertility treatment and new possibilities. Clin Exp Reprod Med. 2014;41(2):41. https://doi.org/10.5653/cerm.2014.41.2.41.
Walls ML, Hart RJ. In vitro maturation. Best Pract Res Clin Obstet Gynaecol. 2018;53:60–72. https://doi.org/10.1016/j.bpobgyn.2018.06.004.
Shapira M, Dolmans MM, Silber S, Meirow D. Evaluation of ovarian tissue transplantation: results from three clinical centers. Fertil Steril. 2020;114(2):388–97. https://doi.org/10.1016/j.fertnstert.2020.03.037.
State Laws & Legislation. Alliance for fertility preservation. Accessed 10 April 2022. https://www.allianceforfertilitypreservation.org/state-legislation/
2019 Assisted reproductive technology fertility clinic and national summary report. Published online 2019:112.
Stadtmauer L, Amato P, Sadek S, McGee EA, Rossi B, Hurst BS. Survey of current practice and satisfaction of SREI members: an SREI committee report. Fertil Steril. 2020;114(3): e70. https://doi.org/10.1016/j.fertnstert.2020.08.215.
Barnhart KT, Nakajima ST, Puscheck E, Price TM, Baker VL, Segars J. Practice patterns, satisfaction, and demographics of reproductive endocrinologists: results of the 2014 Society for Reproductive Endocrinology and Infertility Workforce Survey. Fertil Steril. 2016;105(5):1281–6. https://doi.org/10.1016/j.fertnstert.2015.12.135.
Omurtag K, Grindler NM, Roehl KA, et al. How members of the Society for Reproductive Endocrinology and Infertility and Society of Reproductive Surgeons evaluate, define, and manage hydrosalpinges. Fertil Steril. 2012;97(5):1095-1100.e2. https://doi.org/10.1016/j.fertnstert.2012.02.026.
Stanitis JA, Grow DR, Wiczyk H. Fertility services for human immunodeficiency virus–positive patients: provider policy, practice, and perspectives. Fertil Steril. 2008;89(5):1154–8. https://doi.org/10.1016/j.fertnstert.2007.05.017.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by LC and JL. The first draft of the manuscript was written by LC. All authors commented on previous versions of the manuscript and read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cooper, L.J., Emery, B.R., Aston, K. et al. Fertility preservation practices for female oncofertility differ significantly across the USA: results of a survey of SREI members. J Assist Reprod Genet 39, 1749–1757 (2022). https://doi.org/10.1007/s10815-022-02567-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-022-02567-0